Editorial: Angiogenesis and Angiogenesis Inhibitors in Oral Cancer [PDF]
Frontiers in Oral Health, 2021 Non peer ...
Abdelhakim Salem +5 more
doaj +6 more sources
Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope? [PDF]
Frontiers in Oncology, 2021 BackgroundHead and neck squamous cell carcinoma (HNSCC) carries poor survival outcomes despite recent progress in cancer treatment in general. Angiogenesis is crucial for tumour survival and progression.
Aini Hyytiäinen +13 more
doaj +2 more sources
The efficacy and safety of angiogenesis inhibitors for recurrent ovarian cancer: a meta‑analysis [PDF]
Journal of Ovarian Research, 2022 Objective To investigate the efficacy and safety of angiogenesis inhibitors in the treatment of recurrent ovarian cancer (OC). Methods Electronic databases including PubMed, Web of Science, and the Cochrane Library were searched to find eligible studies ...
Chunmei Zhang, Wancheng Zhao
doaj +2 more sources
Cardiovascular Toxicity of Angiogenesis Inhibitors Among Patients With Cancer in Taiwan: A Nested Case‐Control Study [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground Research on the cardiovascular toxicity of angiogenesis inhibitors among patients with cancer in Taiwan is lacking. This observational study explored the risk of major adverse cardiovascular events (MACEs) associated with angiogenesis ...
Yen‐Chou Chen +4 more
doaj +2 more sources
Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis [PDF]
BMC Pulmonary Medicine, 2023 Background For patients with advanced non-small-cell lung cancer (NSCLC) with EGFR mutations, the suggested course of action is epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs).
Di Hu +6 more
doaj +2 more sources
Cardiotoxic effects of angiogenesis inhibitors. [PDF]
Clin Sci (Lond), 2021 Abstract The development of new therapies for cancer has led to dramatic improvements in survivorship. Angiogenesis inhibitors represent one such advancement, revolutionising treatment for a wide range of malignancies. However, these drugs are associated with cardiovascular toxicities which can impact optimal cancer treatment in the ...
Dobbin SJH +4 more
europepmc +5 more sources
Angiogenesis Inhibitors in NSCLC. [PDF]
Int J Mol Sci, 2017 Angiogenesis is a complex biological process that plays a relevant role in sustaining the microenvironment, growth, and metastatic potential of several tumors, including non-small cell lung cancer (NSCLC). Bevacizumab was the first angiogenesis inhibitor approved for the treatment of patients with advanced NSCLC in combination with chemotherapy ...
Manzo A +10 more
europepmc +4 more sources
An intuitionistic approach for the predictability of anti-angiogenic inhibitors in cancer diagnosis
Scientific Reports, 2023 Malignant cancer angiogenesis has historically attracted enormous scientific attention. Although angiogenesis is requisite for a child’s development and conducive to tissue homeostasis, it is deleterious when cancer lurks.
Syed Anas Ansar +5 more
doaj +1 more source
Thalidomide is an inhibitor of angiogenesis. [PDF]
Proceedings of the National Academy of Sciences, 1994 Thalidomide is a potent teratogen causing dysmelia (stunted limb growth) in humans. We have demonstrated that orally administered thalidomide is an inhibitor of angiogenesis induced by basic fibroblast growth factor in a rabbit cornea micropocket assay.
R J, D'Amato +3 more
openaire +2 more sources
Journal of Dental Sciences, 2021 Background/purpose: The prevalence of oral adverse events and dental treatments related complications during the molecular targeted drugs therapy remains unclear.
Shin-ichi Yamada +8 more
doaj +1 more source